Analysis challenges national security framing of US pharmaceutical supply chain vulnerabilities

The article argues that framing pharmaceutical supply chain risks as a China-centric national security issue obscures systemic domestic vulnerabilities. It suggests that focusing on geopolitical competition distracts from underlying structural weaknesses in the U.S. drug manufacturing ecosystem.